Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Christine Lovly

Associate Professor of Medicine with Tenure

Vanderbilt University Medical Center

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

20%

Pharmacology

50%

Oncology

50%

Targeted Therapy

40%

Cancer Biology

40%

Tyrosine Kinase

30%

Precision Medicine

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

Article Link

Year:

2024

Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease

Article Link

Year:

2024

Refining neoadjuvant immunotherapy for resectable lung cancer.

Article Link

Year:

2024

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years

Article Link

Year:

2024

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

Article Link

Year:

2024

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

Article Link

Year:

2023

Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities

Article Link

Year:

2023

Reply to J.M. Kolesar et al, J.S. Bates et al, and T.C. Knepper et al

Article Link

Year:

2023

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

Article Link

Year:

2022

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Article Link

Year:

2022

N-[18F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer.

Article Link

Year:

2020

Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.

Article Link

Year:

2020

COVID-19 and immune checkpoint inhibitors: initial considerations.

Article Link

Year:

2020

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.

Article Link

Year:

2020

Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.

Article Link

Year:

2020

Collaborators11

Bhuminder Singh

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

Debyani Chakravarty

Sloan Kettering Institute

UNITED STATES

Pamela Hershberger

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES

Stacy Gray

Associate Clinical Professor

City of Hope

UNITED STATES

Misty Shields

Assistant Professor

Indiana State University

UNITED STATES

Benjamin Brown

Research Assistant Professor

Vanderbilt University

UNITED STATES

Adam Smith

Associate Professor

Texas Tech University

UNITED STATES

Vincent K. Lam

Johns Hopkins University School of Medicine

UNITED STATES

Ian Donaldson

The University of Manchester

UNITED KINGDOM

Allison Walker

Assistant Professor

Vanderbilt University

UNITED STATES

Kaitlyn Ledwitch

Research Assistant Professor

Vanderbilt University

UNITED STATES

How do I reach out?

Meet Kite AI